Swiss study to track new kidney drug in 50 patients
NCT ID NCT07555301
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 50 adults with IgA nephropathy who are taking sparsentan. Researchers want to see how the drug affects protein in the urine (albuminuria), a key sign of kidney damage. The study is observational, meaning it just watches what happens in real-world use, without giving any treatment or placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stadtspital Zurich
Zurich, Canton of Zurich, 8000, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tame autoimmune kidney disease?
- Can an Anti-Inflammatory diet protect the kidneys? a trial puts the autoimmune protocol to the test
- Atacicept's Long-Term promise for kidney disease
- Scientists investigate mysterious loin pain in kidney disease
- New hope for kidney patients: drug aims to prevent relapse
- 800-Patient study aims to uncover best treatments for kidney disease